AMAG Pharmaceuticals Announces Completion Of Enrollment In Its Phase III Program Evaluating Feraheme For A Broader Iron Deficiency Anemia Indication

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the completion of patient enrollment in the second of the company’s two phase III studies that comprise its global registrational program for Feraheme® (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause. The two phase III studies include one comparing treatment with  Feraheme to placebo and one comparing treatment with  Feraheme to treatment with intravenous iron sucrose. Both studies have now completed enrollment, with more than 1,400 patients enrolled through 210 study sites globally.

“The completion of enrollment in this program is an important step forward in AMAG’s goal to expand Feraheme’s reach to a much larger number of patients who suffer from IDA,” said Lee F. Allen, M.D., Ph.D., executive vice president and chief medical officer of AMAG. “As we complete data collection and analysis over the next few months, the results of these studies will form the basis for global regulatory submissions, which will seek to expand the indication of Feraheme for the treatment of IDA beyond the current indication for adult patients with chronic kidney disease.”

AMAG plans to submit a sNDA for the broader U.S. label for Feraheme to the U.S. Food and Drug Administration in the second half of 2012. AMAG’s partner, Takeda Pharmaceutical Company, is responsible for all regulatory filings seeking the broad IDA indication for Feraheme in its licensed territories.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that manufactures and markets Feraheme® in the United States. For additional company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc.

About Feraheme

In the United States, Feraheme® (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients. Feraheme received marketing approval from the U.S. Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the U.S. shortly thereafter. For additional product information, please visit www.feraheme.com.

The important safety information below is based on the United States prescribing information.

1 2 3 Next › Last »